Ranibizumab biosimilar - Xbrane Bioscience

Drug Profile

Ranibizumab biosimilar - Xbrane Bioscience

Alternative Names: Xlucane

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xbrane
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 15 Jan 2016 Ranibizumab biosimilar licensed to Helvetic BioPharma in Iran for the treatment of Age-related macular degeneration
  • 30 Oct 2015 Early research in Age-related macular degeneration in Sweden (PO)
  • 30 Oct 2015 Early research in Choroidal neovascularisation in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top